Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives
Regeneron Downgraded At Morgan Stanley; Better Biotech Peer Plays Elsewhere
Oil And Industrial Stocks Have Bottomed - Cramer's Mad Money (10/12/15) (Seeking Alpha)
Related SNY
Sanofi's Genzyme Reports Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting MS who Received Genzyme's Lemtrada
Sanofi's Genzyme Announces New Analysis Suggests Aubagio Slows Brain Atrophy in People with Relapsing MS
Biogen Drops Again: A Reassessment Of The Bull And Bear Investment Cases (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers


Related Articles (REGN + SNY)

Get Benzinga's Newsletters